Suppr超能文献

转铁蛋白靶向聚合物壳聚糖囊泡用于抗癌药物递送

Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles.

作者信息

Dufes Christine, Muller Jean-Marc, Couet William, Olivier Jean-Christophe, Uchegbu Ijeoma F, Schätzlein Andreas G

机构信息

Laboratoire de Biologie des Interactions Cellulaires, CNRS UMR 6558, Faculté des Sciences, Poitiers, France.

出版信息

Pharm Res. 2004 Jan;21(1):101-7. doi: 10.1023/b:pham.0000012156.65125.01.

Abstract

PURPOSE

The study reports the initial biological evaluation of targeted polymeric glycol chitosan vesicles as carrier systems for doxorubicin (Dox).

METHODS

Transferrin (Tf) was covalently bound to the Dox-loaded palmitoylated glycol chitosan (GCP) vesicles using dimethylsuberimidate (DMSI). For comparison, glucose targeted niosomes were prepared using N-palmitoyl glucosamine. Biological properties were studied using confocal microscopy, flow cytometry, and cytotoxicity assays as well as a mouse xenograft model.

RESULTS

Tf vesicles were taken up rapidly with a plateau after 1-2 h and Dox reached the nucleus after 60-90 min. Uptake was not increased with the use of glucose ligands, but higher uptake and increased cytotoxicity were observed for Tf targeted as compared to GCP Dox alone. In the drug-resistant A2780AD cells and in A431 cells, the relative increase in activity was significantly higher for the Tf-GCP vesicles than would have been expected from the uptake studies. All vesicle formulations had a superior in vivo safety profile compared to the free drug.

CONCLUSIONS

The in vitro advantage of targeted Tf vesicles did not translate into a therapeutic advantage in vivo. All vesicles reduced tumor size on day 2 but were overall less active than the free drug.

摘要

目的

本研究报告了靶向聚合物糖基化壳聚糖囊泡作为阿霉素(Dox)载体系统的初步生物学评价。

方法

使用辛二酸二甲酯(DMSI)将转铁蛋白(Tf)共价结合到负载阿霉素的棕榈酰化糖基化壳聚糖(GCP)囊泡上。作为对照,使用N-棕榈酰葡萄糖胺制备葡萄糖靶向脂质体。使用共聚焦显微镜、流式细胞术、细胞毒性测定以及小鼠异种移植模型研究生物学特性。

结果

Tf囊泡在1-2小时后迅速摄取并达到平台期,阿霉素在60-90分钟后到达细胞核。使用葡萄糖配体并未增加摄取,但与单独的GCP阿霉素相比,Tf靶向的摄取更高且细胞毒性增加。在耐药的A2780AD细胞和A431细胞中,Tf-GCP囊泡的活性相对增加明显高于摄取研究预期。与游离药物相比,所有囊泡制剂在体内均具有更好的安全性。

结论

靶向Tf囊泡的体外优势并未转化为体内治疗优势。所有囊泡在第2天均减小了肿瘤大小,但总体活性低于游离药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验